Evidence mapPaperPMID 39716258Full record

ReviewLipids in health and disease2024

The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes.

Verena Gounden, Sridevi Devaraj, Ishwarlal Jialal

Abstract readReview
In one paragraph

Review in Lipids in health and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. [Causal relationship between the triglycerideZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Verena GoundenDepartment of Clinical Biochemistry, University Hospital Galway, Galway, H91YR71, Ireland.
Sridevi DevarajBaylor College of Medicine, Houston, TX, US.
Ishwarlal JialalInternal Medicine and Pathology, UC Davis School of Medicine, 2616 Hepworth Drive, Davis, CA, 95618, US. kjialal@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Triglyceride-glucose (TyG) index represents a simple, cost-effective, and valid proxy for insulin resistance. This surrogate marker has also been proposed as a predictor of metabolic and cardiovascular disease (CVD). In this descriptive review, we aimed to assess the utility of the TyG index as a predictive biomarker of cardiometabolic diseases.

methodsA search was conducted in PubMed, and Web of Science to identify cross-sectional and more importantly prospective studies examining the use of the TyG index as a predictive biomarker. The following terms were utilized in addition to the TyG index: "insulin resistance", "metabolic syndrome", "diabetes"; "cardiovascular diseases".

resultsThis descriptive review included thirty prospective studies in addition to cross-sectional studies. Following adjustment for confounding variables, an elevated TyG index was associated with a significantly increased risk for the development of Metabolic Syndrome (MetS), Type 2 Diabetes, hypertension, and CVD. Also in limited studies, the TyG index was associated with endothelial dysfunction, increased oxidative stress and a pro-inflammatory phenotype.

conclusionOverall, our findings support the use of the TyG index as a valid biomarker to assess the risk of developing MetS, T2DM, as well as atherosclerotic cardiovascular disease.

Indexed as

BiomarkersBlood GlucoseCardiovascular DiseasesInsulin ResistanceMetabolic SyndromeTriglyceridesCross-Sectional StudiesDiabetes Mellitus, Type 2HumansBiomarkersBlood GlucoseTriglyceridesCardiovascular diseaseDiabetesInsulin resistanceMetabolic syndromeTriglyceride-glucose index

Identifiers

PMID39716258
PMCPMC11664894

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.